Abstract
Background: Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action.
Objective: The absorbtion of rivaroxaban is quick, reaching maximum plasma concentration 2-4 hours following its administration. Peroral bioavailability is high (80-100 %) and pharmacokinetic variability is considered to be moderate (coefficient of variation 30-40 %). This review discusses the properties, drug interactions, pharmacokinetics and clinical indications of rivaroxaban. Method: Dosing regimen of rivaroxaban was derived from pharmacologic data of the development program aimed to gain strong antithrombotic drug and balance between efficacy and risk of bleeding in patients. Results of doseranging trials, pharmacokinetic models and randomised studies of phase III advocate the use of such schemes in everyday practice. Results: The drug has been manufactured to fulfill clinical requirements in a variety of indications in adults: prophylaxis of venous thromboembolism (VTE) following elective knee or hip replacement surgical intervention, therapy and secondary prophylaxis of VTE, prophylaxis of ischemic stroke and embolism in individuals diagnosed with nonvalvular atrial fibrillation (NVAF) with risky characteristics, and in Europe the prophylaxis of atherothrombotic episodes following an acute coronary syndrome in subjects with increased levels of cardiac biomarkers. Conclusion: Rivaroxaban may offer benefit in many clinical situations. In comparison with low molecular weight heparin and fondaparinux requiring subcutaneous way of administration, and with vitamin K antagonists (VKAs), which require regular monitoring of international normalized ratio, rivaroxaban is relatively easy to use. However, adjustments of dose are needed in individuals with impaired renal functions.Keywords: Anticoagulants, rivaroxaban, direct factor Xa inhibitor, venous thromboembolism, stroke, atrial fibrillation, pharmacodynamics.
Graphical Abstract
Current Drug Metabolism
Title:Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions
Volume: 18 Issue: 7
Author(s): Tomas Kvasnicka*, Ivana Malikova, Zuzana Zenahlikova, Karolína Kettnerova, Radka Brzezkova, Tomas Zima, Jan Ulrych, Jan Briza, Ivan Netuka and Jan Kvasnicka
Affiliation:
- Thrombotic Centre of Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Karlovo Namesti 32, 121 11 Prague 2,Czech Republic
Keywords: Anticoagulants, rivaroxaban, direct factor Xa inhibitor, venous thromboembolism, stroke, atrial fibrillation, pharmacodynamics.
Abstract: Background: Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action.
Objective: The absorbtion of rivaroxaban is quick, reaching maximum plasma concentration 2-4 hours following its administration. Peroral bioavailability is high (80-100 %) and pharmacokinetic variability is considered to be moderate (coefficient of variation 30-40 %). This review discusses the properties, drug interactions, pharmacokinetics and clinical indications of rivaroxaban. Method: Dosing regimen of rivaroxaban was derived from pharmacologic data of the development program aimed to gain strong antithrombotic drug and balance between efficacy and risk of bleeding in patients. Results of doseranging trials, pharmacokinetic models and randomised studies of phase III advocate the use of such schemes in everyday practice. Results: The drug has been manufactured to fulfill clinical requirements in a variety of indications in adults: prophylaxis of venous thromboembolism (VTE) following elective knee or hip replacement surgical intervention, therapy and secondary prophylaxis of VTE, prophylaxis of ischemic stroke and embolism in individuals diagnosed with nonvalvular atrial fibrillation (NVAF) with risky characteristics, and in Europe the prophylaxis of atherothrombotic episodes following an acute coronary syndrome in subjects with increased levels of cardiac biomarkers. Conclusion: Rivaroxaban may offer benefit in many clinical situations. In comparison with low molecular weight heparin and fondaparinux requiring subcutaneous way of administration, and with vitamin K antagonists (VKAs), which require regular monitoring of international normalized ratio, rivaroxaban is relatively easy to use. However, adjustments of dose are needed in individuals with impaired renal functions.Export Options
About this article
Cite this article as:
Kvasnicka Tomas*, Malikova Ivana, Zenahlikova Zuzana , Kettnerova Karolína , Brzezkova Radka , Zima Tomas , Ulrych Jan , Briza Jan , Netuka Ivan and Kvasnicka Jan , Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions, Current Drug Metabolism 2017; 18 (7) . https://dx.doi.org/10.2174/1389200218666170518165443
DOI https://dx.doi.org/10.2174/1389200218666170518165443 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of n-3 Polyunsaturated Fatty Acids in Human Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Sodium Selenite as an Anticancer Agent
Anti-Cancer Agents in Medicinal Chemistry Role of Tyrosine Isomers in Acute and Chronic Diseases Leading to Oxidative Stress - A Review
Current Medicinal Chemistry Coated with Nanomaterials Intraocular Lenses, Ophthalmic and Human Body Implantable Devices with High Catalytic Antioxidant Activities: A New Nanotechnology Strategy of Peroxidase Cellular Enzyme Mimics Increasing the Biocompatibility and Therapeutic Deployment of the Medical Prosthetic Device
Recent Patents on Drug Delivery & Formulation Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design Anti-Inflammatory Drugs and Statins for Arterial Stiffness Reduction
Current Pharmaceutical Design Incretin-Based Therapies in Patients with Type 2 Diabetes
Current Drug Therapy Evidence-Based Percutaneous Closure of the Left Atrial Appendage in Patients with Atrial Fibrillation
Current Cardiology Reviews Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry Angiotensin-Converting Enzyme - New Insights into Structure, Biological Significance and Prospects for Domain-Selective Inhibitors
Current Enzyme Inhibition Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals
Current Pharmaceutical Design Flavonoids as Multi-Target Compounds in Drug Discovery
Mini-Reviews in Organic Chemistry Novel Strategies in the Ablation of Typical Atrial Flutter: Role of Intracardiac Echocardiography
Current Cardiology Reviews Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function
Current Drug Targets